Home › Occupations › Regulatory Affairs Specialists › Marlborough, MA
Regulatory Affairs Specialists in Marlborough, MA: H-1B salaries
23 labor condition applications for this occupation with a work site in Marlborough, MA. Median offered base salary $104,978; middle half $84,968–$121,393.
By wage level
| Wage level | Median salary |
|---|---|
| Level II (qualified) | $83,308 |
| Level III (experienced) | $98,822 |
| Level IV (fully competent) | $142,677 |
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Employers
| Employer | LCAs | Median salary |
|---|---|---|
| Boston Scientific Corporation | 11 | $142,677 |
| AngioDynamics, Inc. | 3 | $85,186 |
| Candela Corporation | 2 | $88,822 |
| Global Pharmatek LLC | 1 | $108,160 |
| Sumitomo Pharma Oncology, Inc. | 1 | $114,298 |
| GE HealthCare Inc. | 1 | $105,000 |
| CQV Associates Inc. | 1 | $75,982 |
| ModernaTX, Inc. | 1 | $91,478 |
| Unicon Pharma Inc | 1 | $81,744 |
| Kennedy International Software Inc | 1 | $75,982 |
Job titles
- Principal Regulatory Affairs Specialist5
- Regulatory Affairs Specialist II3
- Sr. Regulatory Affairs Specialist2
- Clinical Affairs Specialist1
- Computer Systems Validation Specialist1
- Manager, Quality Management Systems1
- Quality Lead Specialist - Life Sciences Quality1
- Clinical Affairs Associate1
- Sr. Scientific Communication Specialist1
- Sr. Specialist, Regulatory Affairs1
- Senior Regulatory Affairs Specialist1
- Clinical and Regulatory Data Analyst1
- Sr. Specialist, Quality Assurance1
- Sr. Clinical Operations Regulatory Specialist1
- QMS Consultant1
H-1B sponsors in Marlborough, MA →
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).